Key Drivers
- Strong Liquidity
- Negative Cash Flow
- Ongoing Losses
AIAI Summary
PCVX has shifted from a speculative biotech story to a late-stage catalyst-driven test, with a $2.5B cash cushion and OPUS enrollment completion reducing financing risk, but the stock now hinges on whether upcoming Phase 3 data can validate VAX-31 fast enough to justify the valuation before operating losses and timeline risk weigh on sentiment.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Negative Cash Flow
- •Ongoing Losses
PCVX has strong liquidity and minimal leverage, but persistent losses, negative cash flow, and declining book value continue to outweigh its balance-sheet strength.
Price Behavior
Key Price Behavior Insights:
- •Rebound Strength
- •Near-Term Resistance
- •Choppy Trading
PCVX has trended modestly higher over the last month after a sharp rebound from its late-July low, but it is stalling near $59.65 resistance and could pull back if $58.00 support fails.
Sharp rebound from the late-July low to the
Sentiment & News
Key News Insights:
- •VAX-31 timeline
- •VAX-A1 start
- •Cash runway
Vaxcyte remains a mixed story as analysts stay cautious despite pipeline progress, with VAX-31 Phase 3 data due in Q4 2026, VAX-A1 now in Phase 1, and about $2.5B in cash providing a strong runway.
The update is mildly supportive for PCVX because strong liquidity and advancing trials offset the still-uncertain path to late-stage clinical and commercial value
Similar Companies in Healthcare
Other companies in the same sector with AI ratings